These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 19489169

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Development and pharmacology of fluvastatin.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of fluvastatin and specific drug interactions.
    Smith HT, Jokubaitis LA, Troendle AJ, Hwang DS, Robinson WT.
    Am J Hypertens; 1993 Nov; 6(11 Pt 2):375S-382S. PubMed ID: 8297546
    [Abstract] [Full Text] [Related]

  • 4. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 5. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [Abstract] [Full Text] [Related]

  • 6. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP.
    Am J Cardiol; 1994 May 26; 73(14):12D-17D. PubMed ID: 8198018
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
    Faltaos DW, Urien S, Carreau V, Chauvenet M, Hulot JS, Giral P, Bruckert E, Lechat P.
    Fundam Clin Pharmacol; 2006 Jun 26; 20(3):321-30. PubMed ID: 16671968
    [Abstract] [Full Text] [Related]

  • 12. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
    Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmöller J.
    Clin Pharmacol Ther; 2003 Aug 26; 74(2):186-94. PubMed ID: 12891229
    [Abstract] [Full Text] [Related]

  • 13. Fluvastatin for lowering cholesterol.
    Med Lett Drugs Ther; 1994 May 27; 36(923):45-6. PubMed ID: 8177137
    [No Abstract] [Full Text] [Related]

  • 14. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
    Benesic A, Zilly M, Kluge F, Weissbrich B, Winzer R, Klinker H, Langmann P.
    Infection; 2004 Aug 27; 32(4):229-33. PubMed ID: 15293079
    [Abstract] [Full Text] [Related]

  • 15. Clinical pharmacokinetics of fluvastatin.
    Scripture CD, Pieper JA.
    Clin Pharmacokinet; 2001 Aug 27; 40(4):263-81. PubMed ID: 11368292
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of dyslipidaemias with fluvastatin.
    Peters TK.
    Br J Clin Pract Suppl; 1996 Jan 27; 77A():16-9. PubMed ID: 8729585
    [Abstract] [Full Text] [Related]

  • 19. The interaction of diltiazem with lovastatin and pravastatin.
    Azie NE, Brater DC, Becker PA, Jones DR, Hall SD.
    Clin Pharmacol Ther; 1998 Oct 27; 64(4):369-77. PubMed ID: 9797793
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic drug interaction between fexofenadine and fluvastatin mediated by organic anion-transporting polypeptides in rats.
    Qiang F, Lee BJ, Lee W, Han HK.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):413-7. PubMed ID: 19428223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.